BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

bioMerieux, Inc. to Lay Off 100 Workers as It Exits Portland Site


12/7/2010 7:51:40 AM

bioMérieux (Paris:BIM) announced today that, as part of a restructuring of its culture media business in the U.S. and Canada, it will phase out the manufacturing of its prepared media for clinical applications and will transfer the production of all other products manufactured at its Portland, Oregon site to other locations. The site became part of bioMérieux two years ago when it acquired PML Microbiologicals Inc., a provider of culture media and microbiological solutions in North America. These products, for both clinical and industrial applications, included routine prepared media as well as innovative and proprietary technologies such as the LyfoCults® range.

bioMérieux is committed to supplying the most extensive line of culture media and reagents for the North American food and biopharmaceutical markets. The manufacturing of high performance, innovative solutions for the control of manufacturing environments and products will be transferred to bioMérieux's site in Lombard, IL, specialized in industrial applications.

For clinical applications, the production of routine prepared media products at the Portland site, which represent $9 million in annual revenues, will be discontinued. In North America, bioMérieux will focus on its chromIDTM chromogenic culture media range that includes MRSA*, VRE**, and other high medical value tests.

As part of its global manufacturing plan, the production of the LyfoCults lines for both clinical and industrial markets will be transferred to another bioMérieux site dedicated to microbiology. bioMérieux will work closely with its customers to ensure a smooth transition and steady supply of products during the restructuring.

Production at the Portland site should end during the second half of 2011. Approximately 100 employees will be affected by this decision and will be assisted by bioMérieux in their career transition.

In an initial estimation, this decision will result in the recognition of a non-recurring charge of approximately $5 million in the 2010 financial statements, while the closing is estimated to bring about $3 million in annual savings.

* MRSA: Methicillin-resistant Staphylococcus aureus

** VRE: Vancomycin-Resistant Enterococcus

About bioMérieux

Advancing Diagnostics to Improve Public Health

A world leader in the field of in vitro diagnostics for over 45 years, bioMérieux is present in more than150 countries through 39 subsidiaries and a large network of distributors. In 2009, revenues reached €1.223 billion with 85% of sales outside of France.

bioMérieux provides diagnostic solutions (reagents, instruments, software) which determine the source of disease and contamination to improve patient health and ensure consumer safety. Its products are used for diagnosing infectious diseases and providing high medical value results for cancer screening and monitoring and cardiovascular emergencies. They are also used for detecting microorganisms in agri-food, pharmaceutical and cosmetic products.

bioMérieux is listed on the NYSE Euronext Paris market (Symbol: BIM – ISIN: FR0010096479).

Other information can be found at www.biomerieux.com.



   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->